Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
SCT-c001
- Development stage
- Preclinical
- Lead developer
- SymbioCellTech
- Modality
- Cell Therapies
- Administration
- Intraperitoneal
01
Overview
SCT-c001 is an investigational, stem cell-enabled cellular therapy consisting of canine Neo-Islets, which are three-dimensional cellular organoids composed of an approximate 1:1 ratio of allogeneic mesenchymal stem cells (MSCs) and culture-expanded pancreatic islet cells. Developed by SymbioCellTech in collaboration with Virbac, SCT-c001 is specifically designed for the treatment of insulin-dependent diabetes mellitus in dogs. The therapy leverages a proprietary 'natural encapsulation' mechanism wherein the adult MSC component provides local immune isolation, protecting the transplanted islet cells from host immune destruction and rejection without the need for artificial encapsulation devices or systemic immunosuppressive drugs. Administered via a minimally invasive intraperitoneal injection, the Neo-Islets spontaneously engraft into the omentum, undergo neo-vascularization, and secrete insulin and other islet hormones in a physiologically regulated manner to restore long-term euglycemia.
- Other names
- Neo-IsletsNeo-Islet
Beyond the preview
Go deeper on SCT-c001.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on SCT-c001.